05:00:16 EDT Mon 13 Apr 2026
Enter Symbol
or Name
USA
CA



News last 24 hour(s) - 14 items News ReleasesIn The NewsOther CAUS
DateSymCompanyPriceTypeHeadline
2026-04-13 03:57C:APPTUberdoc Health Technologies Corp0.345News ReleaseUberdoc CEO, founder to hold webinar April 15
2026-04-13 03:48C:MDAMDA Space Ltd42.37News ReleaseMDA Space launches MDA Midnight platform
2026-04-13 03:37C:ROMJRubicon Organics Inc0.52News ReleaseRubicon's 1964 Supply Co. brand enters U.K. market
2026-04-13 03:29C:ELYElectrum Discovery Corp0.105News ReleaseElectrum Discovery closes acquisition by MinRex
2026-04-13 03:22C:SCRISilver Crown Royalties Inc13.35News ReleaseSilver Crown arranges $4.5-million private placement
2026-04-13 03:05C:UUUVanguard Mining Corp.0.22News ReleaseVanguard Mining Announces Proposed Acquisition of Quark Uranium Ltd.
2026-04-13 03:05C:GMCGermanium Mining Corp.0.32News ReleaseGermanium Mining Corp. Assembles Exploration Team for 2026 Work Program at Its 100% Owned Lac Du Km 35 Germanium Project, Chibougamau Region, Quebec
2026-04-13 03:02C:AMXAmex Exploration Inc.4.17News ReleaseAmex Delivers a Positive Feasibility Study for Development of the Perron Gold Mine
2026-04-13 03:00C:SCRISILVER CROWN ROYALTIES INC.13.35News ReleaseSilver Crown Royalties Announces $4.5m Fully Allocated Private Placement at Premium to Market
2026-04-13 03:00C:WRLGWest Red Lake Gold Mines Ltd.0.99News ReleaseWest Red Lake Gold Reports 215.46 g/t Au over 5.35m, 50.34 g/t Au over 4.05m and 61.70 g/t Au over 3m in Austin 904 Complex - Madsen Mine
2026-04-13 02:10C:EOGEco (Atlantic) Oil & Gas Ltd.1.02News ReleaseEco (Atlantic) Oil and Gas Ltd. Announces Farm Down of Namibian Portfolio to BP
2026-04-13 02:00C:OTEXOPEN TEXT CORPORATION28.83News ReleaseOpenText Enterprise Data and AI Solutions to be Available on AWS European Sovereign Cloud
2026-04-13 02:00C:OTEXOPEN TEXT CORPORATION28.83News ReleaseOpenText and S3NS Partner to Deliver European Sovereign Cloud Solutions with Google Cloud
2026-04-12 19:30C:4565 News ReleaseNxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia